Chronic Obstructive Pulmonary Disease

The Chronic Obstructive Pulmonary Disease pipeline: 63 tracked drugs, 21 approved for this indication.

21 approved / phase 412 Phase 31 Phase 2/318 Phase 21 Phase 1/26 Phase 14 preclinical / unstaged

Compare the share prices of listed companies in Chronic Obstructive Pulmonary Disease →

Total attributable cost

$61.4B

$4,322/patient

Drug spend

Not yet sourced

How this is calculated ↗

All severities, diagnosed (2022 estimate) · US

The Chronic Obstructive Pulmonary Disease pipeline

Key trial results for every approved and late-stage drug: Chronic Obstructive Pulmonary Disease results by drug.

← all assets